Cipla USA, Inc. Recalls
8 recalls on record in the United States
Cipla USA, Inc. recalls Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-fill
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
View recall details →
Cipla USA, Inc. recalls Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-fil
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
View recall details →
Cipla USA, Inc. recalls Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bott
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
View recall details →
Cipla USA, Inc. recalls Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bott
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
View recall details →
Cipla USA, Inc. recalls Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bott
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
View recall details →
Cipla USA, Inc. recalls Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle, Rx
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
View recall details →
Cipla USA, Inc. recalls Cinacalcet Hydrochloride Tablets, 90 mg, 30-count bottle, Rx
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
View recall details →
Cipla USA, Inc. recalls Cinacalcet Hydrochloride Tablets, 60 mg, 30-count bottle, Rx
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
View recall details →